The article offers information on the US Food and Drug Administration giving clearance to Bayer's of Leverkusen, Germany, Adempas (riociguat) for treating pulmonary arterial hypertension (PAH) and thromboembolic pulmonary hypertension. It states that PAH is a lethal disease which leads to heart failure, vascular remodeling and localized thrombosis.